NCT00996918View on ClinicalTrials.gov

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Alzheimer Disease
Interventions
DRUG

Bapineuzumab 0.5 mg/kg

Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.

DRUG

Bapineuzumab 1.0 m/kg

I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.

Trial Locations (82)

622

Pfizer Investigational Site, North Shore

1200

Pfizer Investigational Site, Brussels

2020

Pfizer Investigational Site, Antwerp

2077

Pfizer Investigational Site, Hornsby

2196

Pfizer Investigational Site, Johannesburg

2650

Pfizer Investigational Site, Edegem

3081

Pfizer Investigational Site, Heidelberg Heights

5000

Pfizer Investigational Site, Adelaide

5011

Pfizer Investigational Site, Woodville South

6009

Pfizer Investigational Site, Nedlands

10600

Pfizer Investigational Site, Plasencia

13000

Pfizer Investigational Site, Marseille

13885

Pfizer Investigational Site, Marseille

14033

Pfizer Investigational Site, Caen

20133

Pfizer Investigational Site, Milan

20520

Pfizer Investigational Site, Turku

21000

Pfizer Investigational Site, Dijon

28006

Pfizer Investigational Site, Madrid

Pfizer Investigational Site, Madrid

28034

Pfizer Investigational Site, Madrid

28040

Pfizer Investigational Site, Madrid

28041

Pfizer Investigational Site, Madrid

28046

Pfizer Investigational Site, Madrid

31059

Pfizer Investigational Site, Toulouse

34295

Pfizer Investigational Site, Montpellier

35000

Pfizer Investigational Site, Rennes

44093

Pfizer Investigational Site, Nantes - Saint Herblain

59037

Pfizer Investigational Site, Lille

75013

Pfizer Investigational Site, Paris

76031

Pfizer Investigational Site, Rouen

86021

Pfizer Investigational Site, Poitiers

7530193

Pfizer Investigational Site, Santiago

7630000

Pfizer Investigational Site, Santiago

FIN-70210

Pfizer Investigational Site, Kuopio

06000

Pfizer Investigational Site, Nice

00179

Pfizer Investigational Site, Roma

Unknown

Pfizer Investigational Site, Aichi

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Hiroshima

Pfizer Investigational Site, Hyōgo

Pfizer Investigational Site, Kagawa

Pfizer Investigational Site, Kanagawa

Pfizer Investigational Site, Kyoto

Pfizer Investigational Site, Nagano

Pfizer Investigational Site, Okayama

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Shizuoka

Pfizer Investigational Site, Tokyo

5223 GZ

Pfizer Investigational Site, 's-Hertogenbosch

8934 AD

Pfizer Investigational Site, Leeuwarden

61-289

Pfizer Investigational Site, Poznan

85-796

Pfizer Investigational Site, Bydgoszcz

31-531

Pfizer Investigational Site, Krakow

01-211

Pfizer Investigational Site, Warsaw

02-097

Pfizer Investigational Site, Warsaw

2700-276

Pfizer Investigational Site, Amadora

3000-075

Pfizer Investigational Site, Coimbra

1649-028

Pfizer Investigational Site, Lisbon

825 56

Pfizer Investigational Site, Bratislava

979 12

Pfizer Investigational Site, Rimavská Sobota

0081

Pfizer Investigational Site, Pretoria

03203

Pfizer Investigational Site, Elche

07010

Pfizer Investigational Site, Palma de Mallorca

07014

Pfizer Investigational Site, Palma de Mallorca

08003

Pfizer Investigational Site, Barcelona

08014

Pfizer Investigational Site, Barcelona

08034

Pfizer Investigational Site, Barcelona

08041

Pfizer Investigational Site, Barcelona

08221

Pfizer Investigational Site, Terrassa

09006

Pfizer Investigational Site, Burgos

SE-205 02

Pfizer Investigational Site, Malmo

CH-4031

Pfizer Investigational Site, Basel

SE5 9RS

Pfizer Investigational Site, London

BN2 5BE

Pfizer Investigational Site, Brighton

G20 OXA

Pfizer Investigational Site, Glasgow

W6 8RF

Pfizer Investigational Site, London

NE4 5PL

Pfizer Investigational Site, Newcastle upon Tyne

CF64 2XX

Pfizer Investigational Site, Penarth

S10 2JF

Pfizer Investigational Site, Sheffield

S35 8QS

Pfizer Investigational Site, Sheffield

SN3 6BW

Pfizer Investigational Site, Swindon

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00996918 - A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients | Biotech Hunter | Biotech Hunter